Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: The MARLINA ‐ T2D study ( ClinicalTrials.gov , NCT 01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard‐of‐care in individuals with type 2 diabetes and albuminuria. Methods: A total of 360 individuals with type 2 diabetes, HbA1c 6.5% to 10.0% (48–86 mmol/mol), estimated glomerular filtration rate ( eGFR ) ≥30 mL/min/1.73 m 2 and urinary albumin‐to‐creatinine ratio ( UACR ) 30–3000 mg/g despite single agent renin‐angiotensin‐system blockade were randomized to double‐blind linagliptin ( n = 182) or placebo ( n = 178) for 24 weeks. The primary and key secondary endpoints were change from baseline in HbA1c at week 24 and time‐weighted average of percentage change from baseline in UACR over 24 weeks, respectively. Results: Baseline mean HbA1c and geometric mean ( gMean ) UACR were 7.8% ± 0.9% (62.2 ± 9.6 mmol/mol) and 126 mg/g, respectively; 73.7% and 20.3% of participants had microalbuminuria or macroalbuminuria, respectively. After 24 weeks, the placebo‐adjusted mean change in HbA1c from baseline was −0.60% (−6.6 mmol/mol) (95% confidence interval [ CI ], −0.78 to −0.43 [−8.5 to −4.7 mmol/mol]; P < .0001). The placebo‐adjusted gMean for time‐weighted average of percentage change in UACR from baseline was −6.0% (95% CI , −15.0 to 3.0; P = .1954). The adverse‐event profile, including renal safety and change in eGFR , was similar between the linagliptin and placebo groups. Conclusions: In individuals at early stages of diabetic kidney disease, linagliptin significantly improved glycaemic control but did not significantly lower albuminuria. There was no significant change in placebo‐adjusted eGFR . Detection of clinically relevant renal effects of linagliptin may require longer treatment, as its main experimental effects in animal studies have been to reduce interstitial fibrosis rather than alter glomerular haemodynamics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Dipeptidyl peptidase-4 (DPP-4) inhibitors are now embedded in the therapeutic armamentarium as suitable options for managing hyperglycaemia in individuals with type 2 diabetes across the full range of CKD stages.(14) DPP-4 is expressed in many tissues and organs, with the highest levels found in the kidney.”
BackgroundFox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Self-citationCanagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 1×
“In general, it is likely that ubiquitous albuminuria-lowering effects over the short term may be achieved only by haemodynamic interventions that actively lower glomerular pressure, such as RAAS blockers and, possibly, SGLT2 inhibitors such as empagliflozin,(31) dapagliflozin(32) or canagliflozin.(33) The small mean r…”
BackgroundSelf-citationDrug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Research works printed but not linked: 31
- 10.1016/j.clinthera.2009.10.020 · DOI
- 10.1111/j.1523-1755.2004.00653.x · DOI · Paper page
- 10.1681/ASN.2006050445 · DOI · Paper page
- 10.1161/01.CIR.0000139860.33974.28 · DOI · Paper page
- 10.1093/eurheartj/ehr017 · DOI · Paper page
- 10.1038/ki.2010.536 · DOI · Paper page
- American Diabetes Association, 2016, Standards of medical care in diabetes – 2016, Diabetes Care, 39, S1
- 10.1016/S2213-8587(16)30045-6 · DOI
- 10.1016/S0167-0115(99)00089-0 · DOI · Paper page
- 10.2337/db13-1029 · DOI · Paper page
- 10.1038/ki.2015.103 · DOI
- 10.1371/journal.pone.0141143 · doi:10.1371/journal.pone.0141143
- 10.1016/j.kint.2016.01.016 · DOI
- 10.2337/dc13-0323 · DOI · Paper page
- 10.1177/1479164115579002 · DOI
- Cooper ME, 2016, Haemodynamic effects of combination therapy with the DPP‐4 inhibitor linagliptin and renin‐angiotensin system inhibitors in patients with type 2 diabetes, Diabetologia, 56, S366
- 10.2337/dc12-0706 · DOI · Paper page
- 10.2337/dc14-1684 · DOI
- 10.1016/j.regpep.2006.12.016 · DOI · Paper page
- 10.1097/HJH.0000000000000328 · DOI
- 10.1016/S0065-1281(11)80302-8 · doi:10.1016/s0065-1281(11)80302-8
- 10.1007/s00125-016-4008-2 · DOI · Paper page
- 10.1111/dom.12654 · DOI · Paper page
- 10.1007/s00125-008-0961-8 · DOI · Paper page
- 10.1210/jc.2015-3716 · DOI
- 10.2337/db16-0317 · DOI · Paper page
- 10.1016/j.kint.2016.06.012 · DOI
- 10.1097/HJH.0b013e3283649b4d · DOI
- 10.1186/1475-2840-12-125 · DOI · Paper page
- 10.1002/oby.20833 · DOI · Paper page
- 10.2337/dc16-0621 · DOI · Paper page
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30086-5 · Cited by 205
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Persson, F., Bain, S. C., Mosenzon, O., Heerspink, H. J. L., Mann, J. F. E., Pratley, R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1622 · Cited by 71
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
Metadata
- Authors
- Groop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R., Cescutti, J., Gordat, M., Meinicke, T., Koitka‐Weber, A., Thiemann, S., & von Eynatten, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-07-31
- Volume
- 19
- Issue
- 11
- Pages
- 1610-1619
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2639738157
- Cited by
- 149
- References
- 12
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.